Article Text

Download PDFPDF

LSO-069 Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice
  1. Beatriz Frade-Sosa1,
  2. Tarek Carlos Salman-Monte2,
  3. Javier Narváez3,
  4. Irene Peralta4,
  5. Sebastian Sandoval5,
  6. Berta Magallares6,
  7. Sergi Heredia7,
  8. Nuria Sapena1,
  9. Anne Riveros-Frutos4,
  10. Alex Olivé4,
  11. Hector Corominas6,
  12. Josefina Cortés-Hernández5 and
  13. Jose A Gómez-Puerta1
  1. 1Rheumatology, Hospital Clinic of Barcelona. Barcelona, Spain
  2. 2Rheumatology, Hospital del Mar/Parc de Salut Mar-IMIM. Barcelona, Spain
  3. 3Rheumatology, Hospital de Bellvitge, L’Hospitalet de Llobregat, Spain
  4. 4Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
  5. 5Rheumatology, Hospital Vall d’Hebron, Barcelona, Spain
  6. 6Rhematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain
  7. 7Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain


Background In 2017, Belimumab (BEL) was approved in subcutaneous (SC) version.1 The effectiveness after switching from intravenous (IV) to SC and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, including the administration of IV biologic therapies. In some patients, a change from IV to SC, including BEL therapy, was required.2 Our aim was to evaluate in daily clinical practice satisfaction to BEL SC therapy in patients previously treated IV BEL. We hypothesized that SC BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction.

Methods Observational, multicenter study, conducted in 7 reference centres in Catalonia (Spain). Inclusion criteria: Stable SLE patients (EULAR/ACR 2019) on treatment with BEL SC and previous use of BEL IV (at least 3 months of treatment with BEL IV before switching).

Since there are no well-validated tools for SC BEL treatment satisfaction, we used RASQ-SC, validated in patients with lymphoma who switched from Rituximab IV to SC treatment,3 modified for BEL treatment.

Results Twenty-seven patients were included. Demographic and general characteristics are summarized in table 1. The mean time from treatment with BEL IV before switch to SC was 26 (SD 21) months. 84% of patients reported confidence in BEL SC. 80% felt that treatment with BEL SC was convenient or very convenient. 85% felt they had gained time with the change. 89% would recommend the SC injection to other patients (figure 1a,b,c,d). Disease activity (mean SLEDAI) and remission rates remain stable after switching (see table 1). No major new side effects were reported.

Conclusions Overall satisfaction, satisfaction with via of administration and satisfaction with the time taken to receive BEL were higher for SC BEL treatment. A switching SC strategy is a reasonable alternative for BEL patients.

Abstract LSO-069 Figure 1

RASQ-SC modified for belimumab

Abstract LSO-069 Table 1

Demographic and disease characteristic


  1. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fiftytwo-week randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2017;69(5):1016–1027. doi:10.1002/art.40049

  2. Mucke J, Brinks R, Fischer-Betz R, Richter JG, Sander O, Schneider M, Chehab G. Patient satisfaction and disease control in patients with systemic lupus erythematosus is not affected by switching from intravenous belimumab to subcutaneous injections. Patient Prefer Adherence. 2019;13:1889–1894

  3. Theodore-Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A. Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. Patient Prefer Adherence. 2016;10:1767–1776

  • systemic lupus erythematosus
  • Belimumab
  • PRO

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.